$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000162828023005382 Filed on February 28, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.193M	$6.937M	$35.11M
YoY Change	-19.03%	-7.14%	53.19%
% of Gross Profit
Research & Development	$9.558M	$17.21M	$49.76M
YoY Change	20.76%	142.37%	41.73%
% of Gross Profit
Depreciation & Amortization	$174.0K	$173.0K	$480.0K
YoY Change	128.95%	121.79%	140.0%
% of Gross Profit
Operating Expenses	$17.75M	$24.15M	$84.87M
YoY Change	-1.57%	65.73%	46.25%
Operating Profit	-$17.75M		-$84.87M
YoY Change	-1.57%		46.25%
Interest Expense	$700.0K		$1.400M
YoY Change			1672.15%
% of Operating Profit
Other Income/Expense, Net	$1.253M	$2.211M	$3.517M
YoY Change	8253.33%	8403.85%	-1004.11%
Pretax Income	-$16.50M	-$21.94M	-$81.35M
YoY Change	-8.44%	50.46%	39.3%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$16.50M	-$21.94M	-$81.35M
YoY Change	-8.44%	50.46%	39.38%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.07		-$0.38
Diluted Earnings Per Share	-$0.07	-$0.10	-$0.38
COMMON SHARES
Basic Shares Outstanding	226.4M shares	218.9M shares	214.6M shares
Diluted Shares Outstanding	225.5M shares		214.6M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.72M	$90.93M	$90.93M
YoY Change	-40.88%	-4.24%	-4.24%
Cash & Equivalents	$68.26M	$77.56M	$77.56M
Short-Term Investments	$8.462M	$13.37M	$13.37M
Other Short-Term Assets	$7.680M	$7.558M	$7.558M
YoY Change	-6.98%	-1.69%	-1.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$84.40M	$98.49M	$98.49M
YoY Change	-38.85%	-4.05%	-4.05%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.952M	$6.053M	$9.963M
YoY Change	313.95%	420.02%	262.16%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.946M	$4.087M	$177.0K
YoY Change	142.38%	127.06%	-51.37%
Total Long-Term Assets	$11.90M	$10.14M	$10.14M
YoY Change	221.57%	225.52%	225.52%
TOTAL ASSETS
Total Short-Term Assets	$84.40M	$98.49M	$98.49M
Total Long-Term Assets	$11.90M	$10.14M	$10.14M
Total Assets	$96.30M	$108.6M	$108.6M
YoY Change	-32.05%	2.71%	2.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.092M	$8.062M	$8.062M
YoY Change	107.7%	248.7%	248.7%
Accrued Expenses	$6.335M	$9.900M	$10.40M
YoY Change	79.11%	128.9%	121.8%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.256M	$0.00
YoY Change
Total Short-Term Liabilities	$15.68M	$18.46M	$18.46M
YoY Change	104.02%	163.71%	163.71%
LONG-TERM LIABILITIES
Long-Term Debt	$1.058M	$2.289M	$2.289M
YoY Change	-38.88%	33.7%	33.7%
Other Long-Term Liabilities	$309.0K	$244.0K	$3.831M
YoY Change	-73.81%	-80.18%	211.21%
Total Long-Term Liabilities	$4.816M	$6.120M	$6.120M
YoY Change	65.44%	107.95%	107.95%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.68M	$18.46M	$18.46M
Total Long-Term Liabilities	$4.816M	$6.120M	$6.120M
Total Liabilities	$20.50M	$24.58M	$24.58M
YoY Change	93.42%	147.21%	147.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$229.5M	-$213.0M
YoY Change	53.31%	61.77%
Common Stock	$2.265M	$2.217M
YoY Change	4.96%	11.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$48.00K	$48.00K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	$75.80M	$84.05M	$84.05M
YoY Change
Total Liabilities & Shareholders Equity	$96.30M	$108.6M	$108.6M
YoY Change	-32.05%	2.71%	2.71%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$16.50M	-$21.94M	-$81.35M
YoY Change	-8.44%	50.46%	39.38%
Depreciation, Depletion And Amortization	$174.0K	$173.0K	$480.0K
YoY Change	128.95%	121.79%	140.0%
Cash From Operating Activities	-$18.24M	-$16.91M	-$60.08M
YoY Change	21.07%	32.1%	25.32%
INVESTING ACTIVITIES
Capital Expenditures	$1.612M	$2.024M	$4.457M
YoY Change	622.87%	-1154.17%	374.65%
Acquisitions
YoY Change
Other Investing Activities	$5.053M	-$13.27M	-$12.51M
YoY Change			1568.0%
Cash From Investing Activities	$3.441M	-$15.29M	-$16.97M
YoY Change	-1643.05%	7866.15%	834.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$59.57M
YoY Change			-146.1%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.496M	8.175M	$59.48M
YoY Change	-89.03%	1251.24%	-50.72%
NET CHANGE
Cash From Operating Activities	-$18.24M	-16.91M	-$60.08M
Cash From Investing Activities	$3.441M	-15.29M	-$16.97M
Cash From Financing Activities	$5.496M	8.175M	$59.48M
Net Change In Cash	-$9.304M	-24.03M	-$17.55M
YoY Change	-126.73%	93.96%	-124.74%
FREE CASH FLOW
Cash From Operating Activities	-$18.24M	-$16.91M	-$60.08M
Capital Expenditures	$1.612M	$2.024M	$4.457M
Free Cash Flow	-$19.85M	-$18.94M	-$64.54M
YoY Change	29.84%	50.16%	32.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36751
CY2022	dei	Entity Registrant Name EntityRegistrantName	OCUGEN, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3522315
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	11 Great Valley Parkway
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Malvern,
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19355
CY2022	dei	City Area Code CityAreaCode	484
CY2022	dei	Local Phone Number LocalPhoneNumber	328-4701
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	OCGN
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	483200000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	226417682	shares
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2022	dei	Auditor Location AuditorLocation	Philadelphia, Pennsylvania
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77563000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94958000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	13371000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7558000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7688000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98492000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	102646000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6053000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1164000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4087000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1800000	usd
CY2022Q4	us-gaap	Assets Assets	108632000	usd
CY2021Q4	us-gaap	Assets Assets	105761000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8062000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2312000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9900000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4325000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	363000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18460000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7000000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3587000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2289000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1712000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	244000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	6120000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	2943000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	24580000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	9943000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	295000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	221721182	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	199502183	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	221599682	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	199380683	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2217000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1995000	usd
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	121500	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	48000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	48000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	294874000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	225537000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	26000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213018000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-131667000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	84052000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95818000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	108632000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105761000	usd
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	49757000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35108000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35111000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	22920000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	84868000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	58028000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-84868000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-58028000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3517000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-389000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-81351000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58417000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-52000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-81351000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58365000	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	25000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000	usd
CY2021	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81325000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58365000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	214600051	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214600051	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	195013043	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	195013043	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	21550000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6958000	usd
CY2021	ocgn	Stock Issued During Period Value Options And Warrants Exercised StockIssuedDuringPeriodValueOptionsAndWarrantsExercised	1262000	usd
CY2021	ocgn	Stock Issued During Period Value Capital Raises Net StockIssuedDuringPeriodValueCapitalRaisesNet	119459000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58365000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95818000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10541000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1262000	usd
CY2022	ocgn	Stock Issued During Period Value Capital Raises Net StockIssuedDuringPeriodValueCapitalRaisesNet	57756000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	26000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-81351000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	84052000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-81351000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-58365000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	480000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	229000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	99000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	usd
CY2022	ocgn	Non Cash Interest Expense NonCashInterestExpense	83000	usd
CY2021	ocgn	Non Cash Interest Expense NonCashInterestExpense	78000	usd
CY2022	ocgn	Noncash Lease Expense NoncashLeaseExpense	593000	usd
CY2021	ocgn	Noncash Lease Expense NoncashLeaseExpense	360000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10541000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6958000	usd
CY2022	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	0	usd
CY2021	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	-52000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	426000	usd
CY2022	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	0	usd
CY2021	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	761000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-479000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-26000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-91000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	742000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9487000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3498000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-383000	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-366000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-100000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-60079000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47941000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	13271000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4457000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	939000	usd
CY2022	ocgn	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	usd
CY2021	ocgn	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	127000	usd
CY2022	ocgn	Issuance Of Financing Receivable IssuanceOfFinancingReceivable	0	usd
CY2021	ocgn	Issuance Of Financing Receivable IssuanceOfFinancingReceivable	750000	usd
CY2022	ocgn	Payments Of Financing Receivable PaymentsOfFinancingReceivable	761000	usd
CY2021	ocgn	Payments Of Financing Receivable PaymentsOfFinancingReceivable	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-16967000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1816000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	59567000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	129211000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	549000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	8525000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	500000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	43000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	0	usd
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	10000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	59475000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	120676000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17546000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	70919000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95109000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24190000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77563000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95109000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4988000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	603000	usd
CY2022	ocgn	Gain Loss On Forgiveness Of Paycheck Protection Program Note GainLossOnForgivenessOfPaycheckProtectionProgramNote	0	usd
CY2021	ocgn	Gain Loss On Forgiveness Of Paycheck Protection Program Note GainLossOnForgivenessOfPaycheckProtectionProgramNote	426000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	911000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	16000	usd
CY2022	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	2916000	usd
CY2021	ocgn	Noncash Or Part Noncash Operating Lease Right Of Use Asset NoncashOrPartNoncashOperatingLeaseRightOfUseAsset	1226000	usd
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	37000	usd
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	usd
CY2022	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ocugen, Inc., together with its wholly owned subsidiaries ("Ocugen" or the "Company"), is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The Company is headquartered in Malvern, Pennsylvania, and manages its business as one operating segment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifier Gene Therapy Platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as retinitis pigmentosa ("RP"), Leber congenital amaurosis ("LCA"), and Stargardt disease, as well as dry age-related macular degeneration ("AMD") with a single mutation-agnostic therapy. The Company's modifier gene therapy platform is based on the use of nuclear hormone receptors ("NHRs"), which have the potential to restore homeostasis — the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, the Company believes that its modifier gene therapy platform, through its use of NHRs, represents a novel approach that has the potential to address multiple retinal diseases caused by mutations in multiple genes with one product, and potentially address complex diseases that are potentially caused by imbalances in multiple gene networks.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that OCU400 has the potential to be broadly effective in restoring retinal integrity and function across a range of genetically diverse IRDs, including RP and LCA. OCU400 has received Orphan Drug Designation ("ODD") from the United States Food and Drug Administration ("FDA") for nuclear receptor subfamily 2 group E member 3 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">")-related RP and LCA and Orphan Medicinal Product Designation ("OMPD") from the European Commission, based on the recommendation of the European Medicines Agency, for RP and LCA. The Company had previously received ODDs from the FDA for the treatment of certain disease genotypes: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, centrosomal protein 290 ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEP290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), rhodopsin ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"), and phosphodiesterase 6B mutation-associated inherited retinal degenerations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is conducting a Phase 1/2 clinical trial to assess the safety of unilateral subretinal administration of OCU400 in patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NR2E3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RHO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related RP and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEP290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related LCA in the United States. The Company has completed dosing patients with RP in the dose-escalation portion of the clinical trial, which enrolled 10 subjects to receive a low, medium, or high dose of OCU400 in the subretinal space. The Company is continuing to enroll subjects with RP and LCA in this clinical trial to receive the high dose, which was determined to be the maximum tolerable dose from the dose-escalation portion of the clinical trial. The Company intends to initiate a Phase 1/2 pediatric clinical trial for OCU400 for the treatment of RP and LCA in the second quarter of 2023 and a Phase 3 clinical trial for OCU400 for the treatment of RP and LCA near the end of 2023, subject to discussions with the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also developing OCU410 and OCU410ST to utilize the nuclear receptor genes RAR-related orphan receptor A for the treatment of dry AMD and Stargardt disease, respectively. The Company is currently executing Investigational New Drug ("IND")-enabling studies and intends to submit IND applications in the second quarter of 2023 to initiate Phase 1/2 clinical trials.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regenerative Medicine Cell Therapy Platform</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NeoCart is a Phase 3-ready, regenerative medicine cell therapy technology that combines breakthroughs in bioengineering and cell processing to enhance the autologous cartilage repair process. NeoCart is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing chondrocytes, the cells responsible for maintaining cartilage health. The chondrocytes are derived from the patient on a unique scaffold. In this therapy, healthy cartilage tissue is grown and implanted in the patient. The Company believes NeoCart has the potential to accelerate healing and reduce pain by reconstructing a patient's previously damaged knee cartilage. It is designed to treat pain at the source, improve function, and potentially prevent a patient's progression to osteoarthritis. The FDA granted a regenerative medicine advanced therapy designation to NeoCart for the repair of full-thickness lesions of knee cartilage injuries in adults. The Company received concurrence from the FDA on the confirmatory Phase 3 clinical trial design. The Company is renovating an existing facility into a current Good Manufacturing Practice facility in accordance with the FDA's regulations in support of NeoCart manufacturing for Phase 3 clinical trial material. The Company intends to initiate the Phase 3 clinical trial in the first half of 2024, subject to discussions with the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaccines</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intramuscular COVID-19 Vaccine</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a Co-Development, Supply and Commercialization Agreement with Bharat Biotech International Limited ("Bharat Biotech") (as amended, the "Covaxin Agreement"), pursuant to which the Company obtained an exclusive right and license under certain of Bharat Biotech's intellectual property rights, with the right to grant sublicenses, to develop, manufacture, and commercialize COVAXIN for the prevention of COVID-19, caused by SARS-CoV-2, in the United States, its territories, and possessions, Canada, and Mexico (the "Ocugen Covaxin Territory"). COVAXIN is a whole-virion inactivated intramuscular COVID-19 vaccine candidate and is formulated with the inactivated SARS-CoV-2 virus, an antigen, and an adjuvant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company announced top-line results from its Phase 2/3 immuno-bridging and broadening clinical trial in the United States evaluating COVAXIN for adults ages 18 years and older. The clinical trial was designed to evaluate whether the immune response observed in participants in a Phase 3 clinical trial previously conducted by Bharat Biotech in India is similar to a demographically representative, adult population in the United States. The clinical trial met both co-primary immunogenicity endpoints. There were no cases of adverse events or serious adverse events related to the vaccination with COVAXIN. The Company plans to work with government agencies in the United States to obtain funding in order to comply with the requirements of a Biologics License Application submission, including funding to initiate an adult safety clinical trial subject to discussions with the FDA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company completed its rolling submission to Health Canada for COVAXIN. The rolling submission process, which was conducted through the Company's Canadian subsidiary, Vaccigen Ltd., was recommended and accepted under the Minister of Health's </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and transitioned to a New Drug Submission ("NDS") for COVID-19. In August 2022, the Company withdrew its NDS based on discussions with Health Canada and is evaluating the requirements for resubmitting an updated NDS. In Mexico, the Comisión Federal para la Protección contra Riesgos Sanitarios authorized emergency use for COVAXIN for adults ages 18 years and older, which remains active. The Company is in discussions with Consejo Nacional de Ciencia y Tecnología in Mexico regarding its submission for emergency use authorization for COVAXIN for pediatric use in ages five to 18 years.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inhaled Mucosal Vaccines</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, the Company entered into an exclusive license agreement ("WU License Agreement") with The Washington University in St. Louis ("Washington University"), pursuant to which the Company obtained the rights to develop, manufacture, and commercialize an inhaled mucosal COVID-19 vaccine for the prevention of COVID-19 in the United States, Europe, and Japan. The WU License Agreement was amended in January 2023 to add the countries of South Korea, Australia, and China to the territory rights (together with the United States, Europe, and Japan, the "Mucosal Vaccine Territory"). Utilizing these rights, the Company is developing a novel inhaled mucosal vaccine platform, which includes OCU500, a bivalent COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and bivalent COVID-19 vaccine. As these vaccine candidates are being developed to be administered through inhalation, the Company believes they have the potential to generate rapid local immunity in the upper airways and lungs where viruses enter and infect the body, which the Company believes may help reduce or prevent infection and transmission as well as provide protection against new virus variants. OCU510 is being developed for the global market. The Company intends to initiate IND-enabling studies and work closely with government agencies to obtain funding for the development of these inhaled mucosal vaccines.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novel Biologic Therapy for Retinal Diseases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing OCU200, which is a novel fusion protein containing parts of human tumstatin and transferrin. OCU200 is designed to treat diabetic macular edema ("DME"), diabetic retinopathy ("DR"), and wet AMD. The Company has completed the technology transfer of manufacturing processes to its contract development and manufacturing organization and has produced clinical trial materials to initiate a Phase 1 clinical trial. The Company submitted an IND application to the FDA in February 2023 to initiate a Phase 1 clinical trial targeting DME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred recurring net losses since inception and has funded its operations to date through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes and debt, and grant proceeds. The Company incurred net losses of approximately $81.4 million and $58.4 million for the years ended December 31, 2022 and </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, respectively. As of December 31, 2022, the Company had an accumulated deficit of $213.0 million and cash, cash equivalents, and investments totaling $90.9 million. This amount will not meet the Company's capital requirements over the next 12 months. The Company believes that its cash, cash equivalents, and investments will enable it to fund its operations into the first quarter of 2024. Due to the inherent uncertainty involved in making estimates and the risks associated with the research, development, and commercialization of biotechnology products, the Company may have based this estimate on assumptions that may prove to be wrong, and the Company's operating plan may change as a result of many factors currently unknown to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks, expenses, and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research, development, and commercialization efforts for its product candidates, which will require significant additional funding. If the Company is unable to obtain additional funding in the future or its research, development, and commercialization efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sales of assets, government grants, licensing and/or collaboration arrangements with pharmaceutical companies or other institutions, funding from the government, particularly for the adult safety clinical trial for COVAXIN and for the development of the Company's novel inhaled mucosal vaccine platform, or funding from other third parties. Such financing and funding may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital, or appropriately manage certain discretionary spending, could have a material adverse effect on the Company's ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to research, develop, and commercialize the Company's product candidates, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued. The consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	ocgn	Modifier Gene Therapy Platform Number Of Products ModifierGeneTherapyPlatformNumberOfProducts	1	product
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-81400000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58400000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213000000	usd
CY2022Q4	us-gaap	Investments And Cash InvestmentsAndCash	90900000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, and the accounting and fair value measurement of equity instruments.</span></div>
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1400000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77563000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94958000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	151000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77563000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	95109000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash, cash equivalents, and investments. The Company's cash, cash equivalents, and investments are held in accounts at financial institutions that may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to significant credit risk beyond the standard credit risk associated with commercial banking relationships.</span></div>
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2022Q3	ocgn	License Agreement Initial License Issuance Fee LicenseAgreementInitialLicenseIssuanceFee	1000000	usd
CY2018Q4	ocgn	License Agreement Minimum Royalty And Sublicense Paid LicenseAgreementMinimumRoyaltyAndSublicensePaid	1000000	usd
CY2016Q2	ocgn	License Agreement Milestone Payment LicenseAgreementMilestonePayment	10000000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	13370000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	13371000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	6674000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	1538000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	621000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	374000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	6053000	usd
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1164000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P10Y
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	774000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	360000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	158000	usd
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	105000	usd
CY2022	us-gaap	Lease Cost LeaseCost	932000	usd
CY2021	us-gaap	Lease Cost LeaseCost	465000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3910000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	810000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1587000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	363000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3587000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1231000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4085000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1594000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.064
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.041
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	763000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	787000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	834000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	834000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	978000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5006000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	921000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4085000	usd
CY2022Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	1894000	usd
CY2021Q4	ocgn	Research And Development Expenses Current ResearchAndDevelopmentExpensesCurrent	866000	usd
CY2022Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	3310000	usd
CY2021Q4	ocgn	Accrued Liabilities Clinical AccruedLiabilitiesClinical	703000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	437000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	747000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2752000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1716000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1507000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	293000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	9900000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4325000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10541000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6958000	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	14900000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2022Q4	ocgn	Number Of Equity Compensation Plans NumberOfEquityCompensationPlans	2	equitycompensationplan
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.12
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.87
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	6100000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2600000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1300000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	900000	usd
CY2022	ocgn	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	157000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-81351000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58417000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-52000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.074
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.079
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.033
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.116
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.017
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.184
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.319
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	51884000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52038000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7298000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	7298000	usd
CY2022Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	9699000	usd
CY2021Q4	ocgn	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	11235000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	629000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	448000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	5057000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1960000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2709000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2064000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	10379000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6655000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4350000	usd
CY2022Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1029000	usd
CY2021Q4	ocgn	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	461000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	95339000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	79854000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	94364000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	79395000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	975000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	459000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	975000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	459000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15000000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	147900000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	52600000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	303000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	300000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-81351000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58365000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	214600051	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	214600051	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	195013043	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	195013043	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13121899	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11627794	shares
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4500000	shares
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	5600000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	200000	usd

Files In Submission

Name	View Source	Status
ocgn-20221231_cal.xml	Edgar Link	unprocessable
ocgn-20221231_lab.xml	Edgar Link	unprocessable
ocgn-20221231_def.xml	Edgar Link	unprocessable
ocgn-20221231_pre.xml	Edgar Link	unprocessable
0001628280-23-005382-index-headers.html	Edgar Link	pending
0001628280-23-005382-index.html	Edgar Link	pending
0001628280-23-005382.txt	Edgar Link	pending
0001628280-23-005382-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ocgn-20221231.htm	Edgar Link	pending
ocgn-20221231.xsd	Edgar Link	pending
ocgn-20221231x10kxex1010.htm	Edgar Link	pending
ocgn-20221231x10kxex1021.htm	Edgar Link	pending
ocgn-20221231x10kxex1023.htm	Edgar Link	pending
ocgn-20221231x10kxex1030.htm	Edgar Link	pending
ocgn-20221231x10kxex1031.htm	Edgar Link	pending
ocgn-20221231x10kxex105.htm	Edgar Link	pending
ocgn-20221231x10kxex106.htm	Edgar Link	pending
ocgn-20221231x10kxex107.htm	Edgar Link	pending
ocgn-20221231x10kxex109.htm	Edgar Link	pending
ocgn-20221231x10kxex211.htm	Edgar Link	pending
ocgn-20221231x10kxex231.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ocgn-20221231x10kxex311.htm	Edgar Link	pending
ocgn-20221231x10kxex312.htm	Edgar Link	pending
ocgn-20221231x10kxex321.htm	Edgar Link	pending
ocgn-20221231_g1.jpg	Edgar Link	pending
ocgn-20221231_g10.jpg	Edgar Link	pending
ocgn-20221231_g11.jpg	Edgar Link	pending
ocgn-20221231_g2.jpg	Edgar Link	pending
ocgn-20221231_g3.jpg	Edgar Link	pending
ocgn-20221231_g4.jpg	Edgar Link	pending
ocgn-20221231_g5.jpg	Edgar Link	pending
ocgn-20221231_g6.jpg	Edgar Link	pending
ocgn-20221231_g7.jpg	Edgar Link	pending
ocgn-20221231_g8.jpg	Edgar Link	pending
ocgn-20221231_g9.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
ocgn-20221231_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2023 Q1 Form 10-K Financial Statement

#000162828023005382 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2023 Q1 Form 10-K Financial Statement

#000162828023005382 Filed on February 28, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn